Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Raises $65M in Private Financing

NEW YORK (GenomeWeb News) – Agendia said today it has raised $65 million in a private round of equity financing.

The funds will be used to further expand the company's Symphony suite of breast cancer tests and the continued development of "our personalized medicine pipeline," Agendia CEO David Macdonald said in a statement. The company recently launched its Symphony suite in a formalin-fixed, paraffin-embedded format, and will soon launch its ColoPrint recurrence test for stage II colon cancer prognosis and prediction, he added.

Debiopharm Group led the round. Current investors Van Herk Group, ING Corporate Investments, Breedinvest, and Gilde Healthcare also participated, and new investors included Korys and others.

Last June, the Amsterdam-based molecular diagnostics firm put on hold a planned initial public offering citing unfavorable market conditions, two weeks after filing for the IPO.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.